Search
Compass Therapeutics Inc.
CMPXAdd to Watchlist
1.910USD
-0.030-1.55%
Close 07-31 16:00（ET）Quotes delayed by 15 min
343.97MMarket Cap
LossP/E TTM
More Details of Compass Therapeutics Inc. Company
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Compass Therapeutics Inc. Info
Ticker SymbolCMPX
Company nameCompass Therapeutics Inc.
IPO dateNov 13, 2020
CEOSchuetz (Thomas J)
Number of employees35
Security typeOrdinary Share
Fiscal year-endNov 13
Address80 Guest Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02135
Phone16175008099
Websitehttps://www.compasstherapeutics.com/
Ticker SymbolCMPX
IPO dateNov 13, 2020
CEOSchuetz (Thomas J)
Company Executives of Compass Therapeutics Inc.
Name
Name/Position
Position
Shareholding
Change
Mr. Barry Shin, J.D.
Mr. Barry Shin, J.D.
Chief Financial Officer
Chief Financial Officer
100.00K
-25.00%
Mr. Jonathan Anderman, J.D.
Mr. Jonathan Anderman, J.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
46.00K
+54.35%
Mr. Philip J. (Phil) Ferneau, J.D.
Mr. Philip J. (Phil) Ferneau, J.D.
Independent Director
Independent Director
--
--
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Ellen V. Chiniara, J.D.
Ms. Ellen V. Chiniara, J.D.
Independent Director
Independent Director
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Dr. Thomas J. Schuetz, M.D., Ph.D.
Dr. Thomas J. Schuetz, M.D., Ph.D.
Chief Executive Officer, Vice Chairman of the Board
Chief Executive Officer, Vice Chairman of the Board
--
--
Mr. James P. (Jim) Boylan
Mr. James P. (Jim) Boylan
Independent Director
Independent Director
--
--
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Independent Director
Independent Director
--
--
Mr. Neil Lerner
Mr. Neil Lerner
Senior Vice President, Chief Accounting Officer and Principal Accounting Officer
Senior Vice President, Chief Accounting Officer and Principal Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Barry Shin, J.D.
Mr. Barry Shin, J.D.
Chief Financial Officer
Chief Financial Officer
100.00K
-25.00%
Mr. Jonathan Anderman, J.D.
Mr. Jonathan Anderman, J.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
46.00K
+54.35%
Mr. Philip J. (Phil) Ferneau, J.D.
Mr. Philip J. (Phil) Ferneau, J.D.
Independent Director
Independent Director
--
--
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Ellen V. Chiniara, J.D.
Ms. Ellen V. Chiniara, J.D.
Independent Director
Independent Director
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Compass Therapeutics Inc.?
The top five shareholders of Compass Therapeutics Inc. are: Mr. Barry Shin, J.D.
How many institutions hold shares of Compass Therapeutics Inc. (CMPX)?
As of 2026Q1, 294 institutions hold shares of Compass Therapeutics Inc., with a combined market value of approximately 162.55M, accounting for 90.26% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 3821912.00.